Collaborative Fund Advisors LLC Acquires New Stake in Gilead Sciences, Inc. $GILD

Collaborative Fund Advisors LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,863 shares of the biopharmaceutical company’s stock, valued at approximately $576,000.

A number of other large investors have also bought and sold shares of the company. Bfsg LLC increased its stake in shares of Gilead Sciences by 7.7% in the third quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 72 shares in the last quarter. Chicago Partners Investment Group LLC grew its stake in Gilead Sciences by 41.8% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 14,288 shares of the biopharmaceutical company’s stock valued at $2,229,000 after buying an additional 4,209 shares in the last quarter. Covestor Ltd grew its stake in Gilead Sciences by 21.5% in the 3rd quarter. Covestor Ltd now owns 876 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 155 shares in the last quarter. Caldwell Trust Co grew its stake in Gilead Sciences by 39.3% in the 3rd quarter. Caldwell Trust Co now owns 1,705 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 481 shares in the last quarter. Finally, 3Chopt Investment Partners LLC raised its holdings in Gilead Sciences by 0.8% during the 3rd quarter. 3Chopt Investment Partners LLC now owns 22,751 shares of the biopharmaceutical company’s stock valued at $3,391,000 after acquiring an additional 180 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This represents a 58.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $169.74, for a total value of $2,546,100.00. Following the transaction, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at approximately $93,642,672.42. This trade represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 126,881 shares of company stock worth $19,252,455. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: DZ Bank raised its price target on Gilead to $191 from $167, signaling increased confidence in the stock’s prospects. DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
• Positive Sentiment: Gilead and its Kite subsidiary plan 23 presentations, including seven oral presentations, at the December ASH meeting. The breadth of planned data across the pipeline and portfolio may draw investor attention to potential growth drivers. Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
• Positive Sentiment: BioNTech and Gilead are advancing a global Phase 3 trial combining BioNTech’s pumitamig with Gilead’s cancer drug Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. The collaboration expands the potential reach of Gilead’s oncology portfolio, though trial results remain to come. BioNTech Enters First Global Phase 3 Trial for New Breast Cancer Combo
• Neutral Sentiment: Gilead’s GS-1206 cancer study continues to advance, but investors are still waiting for early efficacy signals; the update did not provide results that establish the drug’s potential. Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals
• Negative Sentiment: Put-option purchases were unusually elevated, which may reflect increased hedging or bearish positioning, though options activity alone does not confirm a negative outlook.
• Negative Sentiment: CEO Daniel O’Day disclosed recent stock sales under a pre-arranged Rule 10b5-1 plan. The planned nature of the sales may limit their significance, but insider selling can still weigh on sentiment.

Gilead Sciences Stock Up 4.2%

Shares of NASDAQ:GILD opened at $174.48 on Thursday. The stock’s 50-day moving average price is $152.29 and its 200-day moving average price is $140.52. Gilead Sciences, Inc. has a 12-month low of $116.88 and a 12-month high of $175.65. The company has a current ratio of 1.38, a quick ratio of 0.95 and a debt-to-equity ratio of 1.84. The stock has a market capitalization of $216.41 billion, a P/E ratio of -55.22 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.47 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is currently -103.80%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wells Fargo & Company increased their target price on Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Royal Bank Of Canada boosted their price objective on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research note on Friday, October 30th. Citigroup lifted their target price on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a report on Friday, October 30th. HSBC upped their price target on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Jefferies Financial Group set a $196.00 price target on shares of Gilead Sciences in a report on Wednesday. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $170.15.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.